Citigroup
IOVA icon

Citigroup’s Iovance Biotherapeutics IOVA Stock Holding History

Citigroup’s Portfolio IOVA Stock Details IOVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-50,000
Closed -$352K – 5724
2023
Q2 		$352K Sell
50,000
-40,000
-44% -$286K ﹤0.01% 3596
2023
Q1 		$550K Buy
+90,000
New +$621K ﹤0.01% 3064

Other funds holding IOVA

Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $551B AUM 33.95% 1-Year Est. Return
Nuveen
Nuveen Charlotte, North Carolina $420B AUM 34.97% 1-Year Est. Return
Jupiter Asset Management
Jupiter Asset Management London, United Kingdom $21.4B AUM 19.74% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $765B AUM 28.39% 1-Year Est. Return
Orion Investment Company
Orion Investment Company St. Louis, Missouri $377M AUM 66.77% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.32T AUM 44.66% 1-Year Est. Return
C WorldWide Group
C WorldWide Group Copenhagen, Denmark $3.96B AUM 10.41% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $608B AUM 32.77% 1-Year Est. Return
Mirador Capital Partners
Mirador Capital Partners Pleasanton, California $859M AUM 41.74% 1-Year Est. Return

Citigroup's IOVA Position: Q3 2026 in Review

Citigroup increased its Iovance Biotherapeutics (IOVA) stake by 11% in Q3 2026, buying an estimated $683K and bringing the position to 977,613 shares worth $14.5M. The position accounts for ﹤0.01% of the portfolio, ranked #1385.

Citigroup first reported a position in IOVA in Q2 2015 and has held it in 46 quarters since. 162 funds tracked by Wall St. Rank hold IOVA as of Q3 2026.

  • Citigroup held 977,613 shares of Iovance Biotherapeutics worth $14.5M as of Q3 2026.
  • Citigroup bought 95,481 Iovance Biotherapeutics shares in Q3 2026, an estimated $683K.
  • Iovance Biotherapeutics made up ﹤0.01% of Citigroup's portfolio in Q3 2026, its #1385 holding.
  • Citigroup first reported a position in Iovance Biotherapeutics in Q2 2015 and has held it in 46 quarters since.
  • 162 funds tracked by Wall St. Rank held Iovance Biotherapeutics as of Q3 2026.

Based on Citigroup's 13F filing for Q3 2026, filed 4 Nov 2026.